About Lixte Biotechnology Holdings, Inc.
https://lixte.comLixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases.
CEO
Geordan G. Pursglove
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public November 27, 2020
Method of going public SPAC
Full time employees 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $100551
52w High $0.38
52w Low $0.01
P/E 0
Volume 1.17K
Outstanding Shares 4.55M
About Lixte Biotechnology Holdings, Inc.
https://lixte.comLixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $1.8M ▲ | $-2.03M ▼ | 0% | $-0.33 ▼ | $-2.03M ▼ |
| Q2-2025 | $0 | $774.81K ▲ | $-775.67K ▼ | 0% | $-0.29 | $-773.86K ▼ |
| Q1-2025 | $0 | $706.94K ▲ | $-709.55K ▼ | 0% | $-0.29 ▼ | $520 ▲ |
| Q4-2024 | $0 | $613.5K ▼ | $-617.69K ▲ | 0% | $-0.27 ▲ | $0 ▲ |
| Q3-2024 | $0 | $983.26K | $-986.03K | 0% | $-0.44 | $-984.98K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $5.34M ▲ | $5.43M ▲ | $521.42K ▼ | $4.91M ▲ |
| Q2-2025 | $887.21K ▼ | $1.19M ▼ | $537.12K ▲ | $651.46K ▼ |
| Q1-2025 | $1.38M ▲ | $1.51M ▲ | $355.1K ▲ | $1.16M ▲ |
| Q4-2024 | $1.04M ▼ | $1.15M ▼ | $318.28K ▼ | $827.22K ▼ |
| Q3-2024 | $1.64M | $1.7M | $328.96K | $1.37M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.98M ▼ | $-926.75K ▼ | $-2.64M ▼ | $5.56M ▲ | $2M ▲ | $-926.75K ▼ |
| Q2-2025 | $-775.67K ▼ | $-487.49K ▲ | $0 | $-10K ▼ | $-497.49K ▼ | $-487.48K ▲ |
| Q1-2025 | $-709.55K ▼ | $-568.48K ▲ | $0 | $914.23K ▲ | $345.75K ▲ | $-568.48K ▲ |
| Q4-2024 | $-617.69K ▲ | $-598.67K ▲ | $0 | $0 | $-598.67K ▲ | $-598.67K ▲ |
| Q3-2024 | $-986.03K | $-957.6K | $0 | $0 | $-957.6K | $-957.6K |
CEO
Geordan G. Pursglove
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public November 27, 2020
Method of going public SPAC
Full time employees 2
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0